Abstract
Epigallocatechin-3-O-gallate (EGCG)-induced cyclic guanosine monophosphate (cGMP) plays a crucial role in EGCG-induced cell death in various types of cancer cells. However, little is known regarding the early molecular events after cGMP induction. In this study, we showed that cGMP induction is sufficient to induce the phosphorylation of protein kinase C delta (PKCδ) at Ser664, the crucial kinase for EGCG-induced activation of acid sphingomyelinase (ASM). Using a chemical inhibitor library, we revealed that the inhibitors of the negative regulators of diacylglycerol strongly increase the effect of EGCG. We also showed that EGCG treatment increased phospholipase C (PLC) activity, and the same results were obtained with cGMP inducer treatment. EGCG-induced ASM activation was completely suppressed by pharmacological inhibition of PLC. Collectively, EGCG-induced cGMP activated the cGMP/PLC/PKCδ/ASM signaling axis in multiple myeloma cells.
| Original language | English |
|---|---|
| Pages (from-to) | 186-191 |
| Number of pages | 6 |
| Journal | Biochemical and Biophysical Research Communications |
| Volume | 520 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Nov 26 2019 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Biophysics
- Biochemistry
- Molecular Biology
- Cell Biology
Cite this
Epigallocatechin-3-O-gallate induces acid sphingomyelinase activation through activation of phospholipase C. / Bae, Jaehoon; Kumazoe, Motofumi; Takeuchi, Chieri; Hidaka, Shiori; Fujimura, Yoshinori; Tachibana, Hirofumi.
In: Biochemical and Biophysical Research Communications, Vol. 520, No. 1, 26.11.2019, p. 186-191.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Epigallocatechin-3-O-gallate induces acid sphingomyelinase activation through activation of phospholipase C
AU - Bae, Jaehoon
AU - Kumazoe, Motofumi
AU - Takeuchi, Chieri
AU - Hidaka, Shiori
AU - Fujimura, Yoshinori
AU - Tachibana, Hirofumi
PY - 2019/11/26
Y1 - 2019/11/26
N2 - Epigallocatechin-3-O-gallate (EGCG)-induced cyclic guanosine monophosphate (cGMP) plays a crucial role in EGCG-induced cell death in various types of cancer cells. However, little is known regarding the early molecular events after cGMP induction. In this study, we showed that cGMP induction is sufficient to induce the phosphorylation of protein kinase C delta (PKCδ) at Ser664, the crucial kinase for EGCG-induced activation of acid sphingomyelinase (ASM). Using a chemical inhibitor library, we revealed that the inhibitors of the negative regulators of diacylglycerol strongly increase the effect of EGCG. We also showed that EGCG treatment increased phospholipase C (PLC) activity, and the same results were obtained with cGMP inducer treatment. EGCG-induced ASM activation was completely suppressed by pharmacological inhibition of PLC. Collectively, EGCG-induced cGMP activated the cGMP/PLC/PKCδ/ASM signaling axis in multiple myeloma cells.
AB - Epigallocatechin-3-O-gallate (EGCG)-induced cyclic guanosine monophosphate (cGMP) plays a crucial role in EGCG-induced cell death in various types of cancer cells. However, little is known regarding the early molecular events after cGMP induction. In this study, we showed that cGMP induction is sufficient to induce the phosphorylation of protein kinase C delta (PKCδ) at Ser664, the crucial kinase for EGCG-induced activation of acid sphingomyelinase (ASM). Using a chemical inhibitor library, we revealed that the inhibitors of the negative regulators of diacylglycerol strongly increase the effect of EGCG. We also showed that EGCG treatment increased phospholipase C (PLC) activity, and the same results were obtained with cGMP inducer treatment. EGCG-induced ASM activation was completely suppressed by pharmacological inhibition of PLC. Collectively, EGCG-induced cGMP activated the cGMP/PLC/PKCδ/ASM signaling axis in multiple myeloma cells.
UR - http://www.scopus.com/inward/record.url?scp=85072722073&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072722073&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2019.09.102
DO - 10.1016/j.bbrc.2019.09.102
M3 - Article
C2 - 31585731
AN - SCOPUS:85072722073
VL - 520
SP - 186
EP - 191
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
SN - 0006-291X
IS - 1
ER -